{"a": [["Safety, tolerability and sustained weight loss over 2 years with the once\u2010daily human GLP\u20101 analog, liraglutide", "2012"], ["Acute and chronic effects of saxagliptin (ACCES)", "2011"], ["Effect of saxagliptin on pre\u2010diabetes mellitus and obesity", "2013"], ["The effect of the diabetes medication sitagliptin on brown fat and whole\u2010body metabolism in men with overweight and impaired glucose tolerance (or 'pre\u2010diabetes')", "2014"], ["Effects of liraglutide vs lifestyle changes on subcutaneous and visceral fat, liver steatosis, insulin sensitivity and beta cell function after comparable weight loss", "2015"], ["Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial", "2016"], ["Unpublished protocol", "2013"], ["Effect of sitagliptin and metformin on prediabetes progression to type 2 diabetes \u2010 a randomized, double\u2010blind, double\u2010arm, multicenter clinical trial: protocol for the Sitagliptin and Metformin in PreDiabetes (SiMePreD) study", "2016"], ["Combined liraglutide and metformin therapy in women with previous gestational diabetes mellitus (GDM)", "2010"], ["Metformin and sitagliptin in women with previous gestational diabetes", "2011"], ["Effect of saxagliptin treatment on myocardial fat content, and monocyte inflammation", "2012"], ["RISE adult medication study (RISE Adult)", "2014"], ["GDM\u2010TREAT", "2013"], ["Sitagliptin + metformin compared to metformin monotherapy and placebo in women with a recent GDM", "2013"], ["Effects of antidiabetic medications on the postprandial state in prediabetes", "2014"], ["Effects of liraglutide on hippocampal structure and function in aging adults with prediabetes (LGT)", "2014"], ["Improving beta cell function in Mexican American women with prediabetes", "2015"], ["Sitagliptin effects on arterial vasculature and inflammation in obesity (SAVORO)", "2015"], ["Long\u2010acting exenatide and cognitive decline in dysglycemic patients (DRINN)", "2016"], ["Pre\u2010diabetes in subject with impaired fasting glucose (IFG) and impaired glucose tolerance (IGT)", "2016"], ["Effect of linagliptin + metformin vs metformin alone in patients with prediabetes (PRELLIM)", "2016"], ["The impact of DPP\u20104 inhibitor on daily glucose profile and coronary plaque character in impaired glucose tolerance patients with coronary artery disease", "2012"], ["Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study", "2006"], ["Report of the expert committee on the diagnosis and classification of diabetes mellitus", "1997"], ["Report of the expert committee on the diagnosis and classification of diabetes mellitus", "2003"], ["Standards of medical care in diabetes \u2010 2008", "2008"], ["Diagnosis and classification of diabetes mellitus", "2010"], ["Standards of medical care in diabetes \u2010 2014", "2014"], ["Standards of medical care in diabetes \u2010 2015", "2015"], ["Standards of medical care in diabetes \u2010 2017", "2017"], ["Pharmacologic prevention or delay of type 2 diabetes mellitus", "2005"], ["Designing psycho\u2010oncology randomised trials and cluster randomised trials: variance components and intra\u2010cluster correlation of commonly used psychosocial measures", "2013"], ["Can oral hypoglycemic agents restore normoglycemia in individuals with insulin resistance?", "2010"], ["Benchmarks for interpretation of score differences on the SF\u201036 health survey for patients with diabetes", "2013"], ["Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial", "2014"], ["Apparently conclusive meta\u2010analyses may be inconclusive \u2010 trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta\u2010analyses", "2009"], ["Secretion of glucagon\u2010like peptide\u20101 in patients with type 2 diabetes mellitus: systematic review and meta\u2010analyses of clinical studies", "2013"], ["2014 National Diabetes Statistics Report", "2015"], ["The utility of fasting glucose for detection of prediabetes", "2006"], ["Search terms: prediabetes drugs", "2016"], ["Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool", "2014"], ["The incretin concept today", "1979"], ["Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?", "2014"], ["Fasting hyperglycemia in non\u2010insulin\u2010dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake", "1989"], ["Pioglitazone for diabetes prevention in impaired glucose tolerance", "2011"], ["10\u2010year follow\u2010up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study", "2009"], ["Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta\u2010analysis", "2014"], ["Pancreatic safety of incretin\u2010based drugs \u2010 FDA and EMA assessment", "2014"], ["Bias, precision and statistical power of analysis of covariance in the analysis of randomized trials with baseline imbalance: a simulation study", "2014"], ["Cardiovascular safety of dipeptidyl\u2010peptidase IV inhibitors: a meta\u2010analysis of placebo\u2010controlled randomized trials", "2017"], ["Assessment Report. Saxenda. International non\u2010proprietary name: liraglutide", "2015"], ["Drug approval package: Byetta (exenatide) injection", "2005"], ["FDA approves new treatment for diabetes", "2006"], ["Saxenda Injection (Liraglutide [rDNA origin])", "2014"], ["Low positive predictive value of hemoglobin A1c for diagnosis of prediabetes in clinical practice", "2014"], ["GRADEpro GDT", "2015"], ["Sodium\u2010glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus", "2016"], ["Dipeptidyl\u2010peptidase (DPP)\u20104 inhibitors or glucagon\u2010like peptide (GLP)\u20101 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus", "2016"], ["Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus", "2016"], ["Quantifying heterogeneity in a meta\u2010analysis", "2002"], ["Measuring inconsistency in meta\u2010analysis", "2003"], ["A re\u2010evaluation of random\u2010effects meta\u2010analysis", "2009"], ["Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011", "2011"], ["The Cochrane Collaboration's tool for assessing risk of bias in randomised trials", "2011"], ["Sequential methods for random\u2010effects meta\u2010analysis", "2011"], ["The physiology of glucagon\u2010like peptide 1", "2007"], ["Pancreatic beta\u2010cells are rendered glucose\u2010competent by the insulinotropic hormone glucagon\u2010like peptide\u20101(7\u201037)", "1993"], ["Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta\u2010analysis of randomised controlled clinical trials", "2011"], ["Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors", "2013"], ["International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice 1997 CFR &amp; ICH Guidelines", "1997"], ["IDF Diabetes Atlas", "2015"], ["International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes", "2009"], ["Clinical practice. Diagnosis of diabetes", "2012"], ["Beta\u2010cell function is a major contributor to oral glucose tolerance in high\u2010risk relatives of four ethnic groups in the U.S", "2002"], ["The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews", "2010"], ["Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin", "2002"], ["Discrete sequential boundaries for clinical trials", "1983"], ["3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double\u2010blind trial", "2017"], ["The PRISMA statement for reporting systematic and meta\u2010analyses of studies that evaluate interventions: explanation and elaboration", "2009"], ["Industry sponsorship and research outcome", "2017"], ["Comparison of registered and published primary outcomes in randomized controlled trials", "2009"], ["A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation", "2014"], ["Progression rates from HbA1c 6.0\u20106.4% and other prediabetes definitions to type 2 diabetes: a meta\u2010analysis", "2013"], ["Dipeptidyl peptidase\u20104 inhibitor\u2010associated pancreatic carcinoma: a review of the FAERS database", "2015"], ["Incretin effects of increasing glucose loads in man calculated from venous insulin and C\u2010peptide responses", "1986"], ["A trial to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy male Japanese and Caucasian subjects", "2014"], ["Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group", "1979"], ["Effect of truncated glucagon\u2010like peptide\u20101 [proglucagon\u2010(78\u2010107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach", "1988"], ["Oral antidiabetic drugs and regression from prediabetes to normoglycemia: a meta\u2010analysis", "2012"], ["Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta\u2010analysis", "1997"], ["Insulin secretion and incretin hormones after oral glucose in non\u2010obese subjects with impaired glucose tolerance", "2004"], ["Efficacy and safety of DPP\u20104 inhibitors in patients with type 2 diabetes: Meta\u2010analysis of placebo\u2010controlled randomized clinical trials", "2017"], ["Practical use of glucagon\u2010like peptide\u20101 receptor agonist therapy in primary care", "2014"], ["Review Manager (RevMan)", "2014"], ["Interpretation of random effects meta\u2010analyses", "2011"], ["Meta\u2010analysis of randomised trials with a continuous outcome according to baseline imbalance and availability of individual participant data", "2013"], ["Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus", "2013"], ["Racial differences in glycemic markers: a cross\u2010sectional analysis of community\u2010based data", "2011"], ["MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets", "2009"], ["Recommendations for examining and interpreting funnel plot asymmetry in meta\u2010analyses of randomised controlled trials", "2011"], ["Determinants of the impaired secretion of glucagon\u2010like peptide\u20101 in type 2 diabetic patients", "2001"], ["Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance", "2001"], ["Alpha\u2010glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose", "2006"], ["Predisease: when does it make sense?", "2011"], ["Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate", "2008"], ["Trial sequential analysis may establish when firm evidence is reached in cumulative meta\u2010analysis", "2008"], ["Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation", "1998"], ["Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1. Diagnosis and classification of diabetes mellitus", "1999"], ["Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation", "2006"], ["Comparison of top\u2010performing search strategies for detecting clinically sound treatment studies and systematic reviews in MEDLINE and EMBASE", "2006"], ["Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE", "2006"], ["Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta\u2010epidemiological study", "2008"], ["The epidemic of pre\u2010diabetes: the medicine and the politics", "2014"], ["Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double\u2010blind trial", "2015"]], "ex": [["Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study", "2015"], ["Does exenatide improve post prandial glycaemic control in young people with cystic fibrosis related diabetes or impaired glucose tolerance?", "2015"], ["Treatment with sitagliptin phosphate in patients with symptomatic reactive hypoglycemia. A randomized, placebo\u2010controlled, double\u2010blinded, clinical trial", "2012"], ["Effects of miglitol, vildagliptin, or their combination on serum insulin and peptide YY levels and plasma glucose, cholecystokinin, ghrelin, and obestatin levels", "2014"], ["Successful treatment of prediabetes in clinical practice: targeting insulin resistance and beta\u2010cell dysfunction", "2012"], ["BEGAMI", "2013"], ["Sitagliptin reduces inflammation and chronic immune cell activation in HIV+ adults with impaired glucose tolerance", "2015"], ["The effect of DPP\u20104 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose", "2010"], ["Sitagliptin vs. placebo for non\u2010alcoholic fatty liver disease: a randomized controlled trial", "2016"], ["Exenatide regulates cerebral glucose metabolism in brain areas associated with glucose homeostasis and reward system", "2015"], ["Short\u2010term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes", "2012"], ["Metformin and sitagliptin in patients with impaired glucose tolerance and a recent TIA or minor ischemic stroke \u2010 a multicenter, randomized, open\u2010label phase II trial", "2015"], ["Effect of intact GLP\u20101 (7\u201036) and GLP\u20101 metabolite (9\u201036) on coronary microvascular function in adults with prediabetes", "2013"], ["Lixisenatide vs. exenatide on metabolic control, insulin secretion, and insulin sensitivity in impaired glucose tolerance patients", "2015"], ["Effect of exenatide, sitagliptin or glimepiride on functional \u03b2\u2010cell mass", "2013"], ["Impact of sitagliptin on carotid intima\u2010media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus", "2014"], ["Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance", "2015"], ["Exenatide protects against glucose\u2010 and lipid\u2010induced endothelial dysfunction: evidence for direct vasodilation effect of GLP\u20101 receptor agonists in humans", "2015"], ["Does a GLP\u20101 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double\u2010blinded, placebo\u2010controlled clinical trial", "2014"], ["Efficacy and safety of vildagliptin compared to placebo in patients with type 2 diabetes and mild hyperglycemia", "2005"], ["Prevention of Diabetes Progression Trial (PDPT)", "2005"], ["Sitagliptin prophylaxis for glucocorticoid\u2010induced impairment of glucose metabolism in males with the metabolic syndrome (SPHINX)", "2008"], ["Effect of pioglitazone and exenatide on body weight and beta cell function (PIO\u2010EX)", "2009"], ["The effects of exenatide on post\u2010meal sugar peaks and vascular health in obese/pre\u2010diabetic young adults", "2009"], ["GLP\u20101 therapy for weight loss and improved glucose tolerance in obese children", "2009"], ["Effect of sitagliptin in impaired glucose tolerance", "2009"], ["DPP\u20104 Inhibition and TZD for DM Prevention (DInT DM)", "2009"], ["PINGUIN (Postpartum Intervention in Women with Gestational Diabetes Using Insulin)", "2009"], ["Sitagliptin in Prevention of Type 2 Diabetes Mellitus (SITAGLIPTIN)", "2009"], ["A study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of JNJ\u201038431055, sitagliptin, and co\u2010administration of JNJ\u201038431055 and sitagliptin", "2010"], ["The vascular effects of vildagliptin in insulin resistant individuals", "2010"], ["Glucose control in pre\u2010diabetic renal transplant patients (GCPD)", "2011"], ["The effect of liraglutide on left ventricular function in chronic heart failure patients with and without type 2 diabetes mellitus", "2011"], ["Does a GLP\u20101 receptor agonist change glucose tolerance in antipsychotic\u2010treated patients? (GREAT)", "2013"], ["Use of sitagliptin for stress hyperglycemia or mild diabetes following cardiac surgery", "2013"], ["Liraglutide efficacy on glucocorticoid induced hyperglycemia in patients high risk for diabetes", "2016"], ["Saxagliptin + metformin compared to saxagliptin or metformin monotherapy in PCOS women Wwith impaired glucose homeostasis (BMS\u2010AZPCOS)", "2022"], ["The LiRA2 study", "2014"], ["Research of intensive lifestyle Intervention for PCOS patients with IGT", "2015"], ["Exenatide protects against glucose\u2010 and lipid\u2010induced endothelial dysfunction: evidence for direct vasodilation effect of GLP\u20101 receptor agonists in humans", "2015"], ["Alogliptin, but not voglibose, ameliorates dyslipidemia and LDL particle size in patients with impaired glucose tolerance or Type 2 diabetes", "2013"], ["Therapeutic efficacy of sitagliptin in patients with nonalcoholic fatty liver disease (NAFLD) in impaired glucose tolerance (IGT): a pilot study", "2011"], ["Efficacy and safety of combination therapy with GLP\u20101 analog lixisenatide and long\u2010acting insulin glargine in patients with glucose intolerance or diabetes caused by hyposecretion of endogenous insulin who underwent partial pancreatectomy", "2014"], ["A study to evaluate the effects of vildagliptin on the insulin response to glucose in subjects with pre\u2010diabetes", "2008"], ["Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo\u2010controlled clinical trial", "2013"]], "in": [["Effect of liraglutide administration and a calorie\u2010restricted diet on lipoprotein profile in overweight/obese persons with prediabetes", "2014"], ["Effects of exenatide vs. metformin on endothelial function in obese patients with pre\u2010diabetes", "2012"], ["Effect of linagliptin on glycemic control and variability in patients with impaired glucose tolerance", "2015"], ["Exenatide/diet vs diet alone for treatment of prediabetes", "2011"], ["CLAF237A2357", "2008"], ["Pilot study of effects of exenatide on body weight in non\u2010diabetic, obese patients", "2010"], ["Efficacy and safety of liraglutide 3.0 Mg in adult overweight and obese weight loss responders without diabetes: results of the 56\u2010week randomised, controlled, scale obesity and prediabetes trial", "2015"]]}